IL6 and Hypoglycemia: Prophylactic administration of bezlotoxumab prevented infection-mediated hypoglycemia, uremia, and a spike in IL-6 when compared to infected mice that received PBS (p = .0159; Supplementary Figure 2e-g), and a moderate, yet not significant reduction in creatinine levels compared to infected mice that received PBS (Supplementary Figure 2d).